FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Novavax

FDA lifts hold on Novavax RSV vaccine trial

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


Shares of Novavax ($NVAX) surged this morning on the news that the FDA has lifted its clinical hold on a Phase I study of an experimental RSV vaccine. Back in November the biotech reported that it had received a question from the FDA regarding chemistry, manufacturing and controls which has now been resolved.

"We are excited to advance our vaccine candidate for RSV into clinical testing," said Dr. Rahul Singhvi, the CEO of the Rockville, MD-based vaccines company. "This is a significant accomplishment and represents the second major internally discovered vaccine program based on our core platform technologies. RSV is the leading cause of viral death in infants and a common illness in elderly adults. A safe and effective vaccine is especially needed in these populations since RSV infection does not provoke lasting immunity."

The Phase I study follows the successful conclusion of the preclinical program for the vaccine in August. Its stock was up seven percent in early trading, according to Reuters.

- read the Novavax release
- here's the Reuters report

Related Articles:
Novavax, ROVI end talks over flu vax
Red-hot Novavax negotiating vax tech transfers
Novavax is on a roll with mid-stage VLP success

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Novavax  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.